New CMS rules signal a turning point for AI-powered cardiac diagnostics, paving the way for broader clinical adoption …
New CMS rules signal a turning point for AI-powered cardiac diagnostics, paving the way for broader clinical adoption …
On November 13, 2024, the U.S. Food and Drug Administration (FDA) approved a novel gene therapy for aromatic …
Ocugen’s Gene Therapy Trials Light Up Times Square—New Data Offers Hope for Rare Retinal Diseases
With all three Phase 3 trials now enrolling, Akero Therapeutics is racing to bring its promising MASH therapy, …
Despite a muted IPO market and cautious M&A activity, biotech in 2024 proved that innovation never sleeps—especially when …
From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
Exploring recent advancements in CRISPR therapies, personalized gene editing, and artificial intelligence transforming drug development and clinical trials.
In 2024, the European Medicines Agency (EMA) recommended a record 114 new medicines for approval, showcasing major advances …
Clinical research in 2024 is progressing rapidly, driven by pioneering studies, technological innovation, and evolving regulatory frameworks that …
Clinical research worldwide is rapidly transforming through new digital strategies—especially in the field of rare diseases. Recent months …
Already a subscriber? Log in